CompletedNot applicableNCT00342953

Study of Health Effects of Cosmetic Breast Augmentation

This study will examine long-term health effects of cosmetic breast augmentation (enlargement) with silicone gel breast implants. There has been concern for some time about the possible effects of breast implants on the immune system particularly regarding the development of certain connective tissue disorders and on the possibility that implants may interfere with the ability to detect breast cancers. More recently, concerns have been raised regarding the possible cancer-causing effect of the implants themselves. These concerns were heightened by reports that the polyurethane foam coating that envelops the silicone gel in some implants may dissolve and produce a chemical called 2,4,-diamino toluene (TDA), which has been linked to an increased risk of breast and other cancers in rats and mice. To address this issue, this study will gather information from the medical records and a questionnaire survey of approximately 12,000 breast implant patients. The questionnaire will request information on perceived complications of the implants; history of breast examinations and mammograms; frequency of breast self examination; development of diseases (particularly cancers and connective tissue disorders) developed subsequent to the augmentation surgery; potential risk factors for these diseases, such as age at menarche (onset of menstruation), age at first birth, age and type of menopause (natural or due to surgery); history of breast biopsies; immune system and connective tissue disorders; cigarette smoking; alcohol consumption; family medical history, and so forth. To evaluate the results, the information will be compared with the same data on 4,000 women who underwent other plastic surgery procedures, such as rhinoplasty, facelift, liposuction, dermabrasion, eyelifts, and others, from the same practices as the breast augmentation patients. Participants will be recruited for the study from several large reconstructive and plastic surgery practices. Among the breast implant patients, women who have had bilateral breast implants for cosmetic purposes only, and not as breast reconstruction after breast cancer surgery, will be eligible. Women with a history of breast cancer may not participate.

Checked against the public recordLast updated Jul 14, 2020 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations1
SponsorNational Cancer Institute (NCI)
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
National Cancer Institute (NCI)
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
03
Public criteria

Who may be able to participate

* INCLUSION AND EXCLUSION CRITERIA: The following criteria for inclusion in the study cohort will apply: 1. Age. No age restrictions apply; patients receiving cosmetic implants at any age will be eligible for study. 2. Cosmetic augmentation only. Patients with breast reduction surgery or reconstructive surgery following breast cancer will not be included. 3. Females only. Implants in conjunction with sex change surgery will not be included. 4. Bilateral implants only. Patients with unilateral implants will not be included. 5. First occurrence of a breast implant. Patients with a previous breast implant will not be included. 6. Patients with a history of plastic surgery involving silicone exposure will not be included. 7. Patients with a history of breast cancer at or before the time of implant will not be included. 8. Patients residing in defined geographic areas at the time that their plastic surgery was sought (these areas will need to be individually defined for each study site). 9. Patients with a history of breast surgery for non-cancerous events, those with a history of cancer of sites other than the breast, and those with documented histories of connective tissue disorders will continue to be eligible for cohort inclusion, although information on these conditions will be abstracted so that separate analyses can be pursued. For the comparison cohort, items a, c, f, g, h and i will apply. Patients currently receiving an operation involving implantation of silicon will not be included in the comparison cohort.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • National Cancer Institute (NCI), 9000 Rockville PikeBethesda, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 14, 2020. Always confirm current availability with the study team.

View original record ↗